Health Care & Life Sciences » Biotechnology | Bavarian Nordic A/S

Bavarian Nordic A/S | Cash Flow

Fiscal year is January-December. All values DKK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
33,415.00
16,675.00
59,426.00
30,600.00
181,343.00
361,927
Depreciation, Depletion & Amortization
43,851.00
44,913.00
43,489.00
114,149.00
106,805.00
41,639
Other Funds
-
-
-
664,800.00
207,482.00
49,563
Funds from Operations
215,179.00
121,430.00
101,465.00
177,204.00
529,103.00
270,725
Changes in Working Capital
68,095.00
217,319.00
3,858.00
90,397.00
313,038.00
17,804
Net Operating Cash Flow
147,084.00
338,749.00
105,323.00
267,601.00
216,065.00
288,529
Capital Expenditures
155,435.00
105,987.00
59,921.00
91,519.00
78,698.00
Sale of Fixed Assets & Businesses
1,847.00
53.00
1,200.00
1,979.00
-
Purchase/Sale of Investments
7,081.00
397,731.00
119,402.00
358,643.00
1,266,511.00
Net Investing Cash Flow
146,507.00
503,665.00
178,123.00
448,183.00
1,345,209.00
Issuance/Reduction of Debt, Net
7,105.00
49,019.00
1,885.00
1,974.00
370,062.00
Net Financing Cash Flow
7,105.00
216,238.00
26,569.00
657,199.00
613,441.00
Net Change in Cash
6,746.00
51,558.00
24,294.00
479,533.00
571,075.00
Free Cash Flow
102,674.00
286,357.00
73,671.00
219,791.00
159,708.00
Change in Capital Stock
-
265,257.00
28,454.00
5,627.00
35,897.00
Exchange Rate Effect
218.00
236.00
21,937.00
2,916.00
55,372.00

About Bavarian Nordic A/S

View Profile
Address
Hejreskovvej 10A
Kvistgaard CR 3490
Denmark
Employees -
Website http://www.bavarian-nordic.com
Updated 07/08/2019
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases.